Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 1.00 |
| ▸ | NAAA | Q02083 | 1/20 | 0.77 |
| ▸ | FAAH | O00519 | 5/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.64 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497062 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL12847246 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL8209014 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10149806 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL9288380 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10149803 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL12738558 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL5065624 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL12847247 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL9795571 | 1.00 | CASP2 (1.00) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119193162-A | BOE etching solution for thinning or removing silicon oxide in integrated circuit manufacturing process | 深圳新宙邦科技股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-107619950-A | A kind of extracts composition, extraction system and its application | 中国科学院上海有机化学研究所 | 2018-01-23 | — | — | CN | claimed |
| CN-119193162-A | BOE etching solution for thinning or removing silicon oxide in integrated circuit manufacturing process | 深圳新宙邦科技股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-115557849-A | Method for synthesizing imide compound under induction of NBS and water by visible light | 西南大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022140554-A1 | SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-3131585-B1 | MULTIDENTATE BIFUNCTIONAL CHELATING AGENTS FOR RADIONUCLIDE COMPLEXATION IN DIAGNOSTICS AND THERAPY | UNIV ZUERICH (CH) | 2020-07-15 | — | — | EP | disclosed |
| US-20190328892-A1 | Therapeutic agent for ischemic disease | CHUO UNIVERSITY (JP) | 2019-10-31 | — | — | US | disclosed |
| CN-110381917-A | Use of compatible solutes | 默克专利股份有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110023292-A | Apoptosis inhibitor | 北京生命科学研究所 | 2019-07-16 | — | — | CN | disclosed |
| US-10328014-B2 | Cosmetic process for attenuating wrinkles | L'OREAL (FR) | 2019-06-25 | — | — | US | disclosed |
| US-20110229528-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-22 | — | — | US | disclosed |
| US-20100048468-A1 | GLP-1 COMPOUNDS | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1903074-B1 | RESIN COMPOSITION | ZEON CORP (JP) | 2009-10-14 | — | — | EP | disclosed |
| EP-1903074-A1 | RESIN COMPOSITION | ZEON CORPORATION (JP) | 2008-03-26 | — | — | EP | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328892-A1 | Therapeutic agent for ischemic disease | HBG1, HBG2, ALB | CASP2 1935/4885NAAA 2150/4885FAAH 3249/4885 |
| US-10328014-B2 | Cosmetic process for attenuating wrinkles | COL1A1, CUTA, GLA | CASP2 4730/4885NAAA 556/4885FAAH 1201/4885 |
| US-20100048468-A1 | GLP-1 COMPOUNDS | GLP1R, IAPP, GIPR | CASP2 2613/4885NAAA 789/4885FAAH 835/4885 |
| US-20110229528-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | CASP2 4848/4885NAAA 3360/4885FAAH 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.